SWOG clinical trial number
SWOG-9460
Phase IIb Randomized Chemoprevention Trial of N-(4-Hydroxyphenyl) Retinamide (4-HPR) in Transitional Cell Bladder Carcinoma
Closed
Phase
Accrual
34%
Published
Abbreviated Title
Phase IIb Randomized Chemoprevention Trial of N-(4-Hydroxyphenyl) Retinamide (4-HPR) in Transitional Cell Bladder Carcinoma
Activated
06/01/1996
Closed
10/15/1999
Publication Information Expand/Collapse
2008
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer [PMID18172274]